Off-the-shelf CAR-T from stem cells? An ear­ly look at UCLA tech — li­censed by Gilead

Less than two years af­ter the FDA first ap­proved No­var­tis and Gilead’s ground­break­ing au­tol­o­gous CAR-T treat­ments, the next rev­o­lu­tion in can­cer cell ther­a­py is al­ready rag­ing on as biotechs like Cel­lec­tis and Al­lo­gene be­gin test­ing prod­ucts made from healthy donor cells. UCLA sci­en­tists want to take the off-the-shelf ap­proach one step fur­ther by grow­ing a “vir­tu­al­ly un­lim­it­ed sup­ply” of T cells in the lab.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER